long intergenic non-protein coding RNA 926Genealiases: []
Q-omics provides the consensus-scored LINC00926 profile across patient tissues and cancer cell-line models. LINC00926 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, LINC00926 is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, LINC00926 RNA expression shows 16,829 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight HNSC, KIRC, and UVM as cancer lineages where LINC00926 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC00926 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC00926 survival associations across molecular data types. LINC00926 RNA expression shows survival associations in the most cancer types (27). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC00926 RNA expression–survival associations across cancer types. High LINC00926 expression shows unfavorable associations in KIRC, but favorable associations in HNSC, BLCA, BRCA, LUAD and READ. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for LINC00926 RNA expression.
This table summarizes LINC00926 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC00926. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC00926 shows lower tumor expression in BRCA, BLCA and THCA and higher tumor expression in KIRC, STAD and CHOL. The KIRC box plot shows higher LINC00926 RNA expression in tumor versus normal tissue (log2 FC = +0.541, t-test p < 0.001).
This table shows molecular features associated with LINC00926 in patient tissues and cancer cell lines. In patient samples, LINC00926 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
